Académique Documents
Professionnel Documents
Culture Documents
(Restasis, Allergan)
Ojo seco
Ojo seco
Inclusin:
Exclusin:
Ojo seco
Dosis: 2 veces/dia
Duracin: indefinida (se han seguido
pacientes hasta por 72 meses, sin
RAM)
Podria mejorar definitivamente a un
subgrupo de pacientes tras al menos
6 meses de tto Ophthalmology. 2007
Jan;114(1):76-9
Ojo seco
Queratoconjuntivitis vernal
Queratoconjuntivitis atpica
21 patients used either topical 2% CsA or the vehicle alone four times daily
for 3 months, in addition to their usual therapy with topical corticosteroids
and/or mast cell stabilisers. The great majority of the treated patients were
able to discontinue their topical steroid treatment.
20 patients with topical steroid resistant, severe atopic
keratoconjunctivitis; they had moderately active disease despite topical
steroid therapy with or without mast cell stabilisers (nedocromil,
lodoxamide). Treatment (CsA or placebo) lasted for 28 days with a dosing
schedule of six times daily during the first 2 weeks and four times daily
during the last 2 weeks. Significant improvement was observed in the CsA
group, and none of these patients had a worsening of the disorder, in
contrast with the placebo group
52 Tx de bajo riesgo.
CsA 0,05% iniciada 1-10 semanas post-Tx
1 subgrupo con pulsos prednisolona 1% x
4 x 4 dias, cada 6 semanas
Prednisolona sola: menos rechazo que CsA
CsA sola: menos rechazo que Prednisolona
pulsos + CsA Ophthalmology. 2006 Oct;113(10):1785-90
CsA: 2mm
Pred: 0.25
Am J
Queratopatia neurotrofica
temprana
Entonces...
-Exclusion: